UNSPSC 51161564: Ablukast sodium

This classification denotes an anti-asthmatic agent with the molecular formula C28H33O8.Na, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 37BXZ0J2RT, chemically known as 2h-1-benzopyran-2-carboxylic acid, 6-acetyl-7-((5-(4-acetyl-3-hydroxy-2-propylphenoxy)pentyl)oxy)-3,4-dihydro-, monosodium salt, ( -); but more generally known as ablukast sodium, which bears US NIH Compound Identifier 57108. Most nations, for tariff and trade purposes, schedule ablukast sodium under HS 29329985 and SITC 51569.

As of Q4 2014, ABLUKAST SODIUM remains US FDA's Preferred Term for this commodity. Ablukast sodium bears US NLM identifiers UMLS ID C2827073 and NCI Concept Code C83514. SMILES: CCCC1C(CCC(C1O)C(=O)C)OCCCCCOC2CC3C(CC2C(=O)C)CCC(O3)C(=O)[O-].[NA+].

UNSPSC 51161564 Ablukast sodium, a Commodity code, covers the supply of this leukotriene receptor antagonist pharmaceutical product to state and local healthcare facilities, schools, and public institutions through cooperative purchasing agreements and direct procurement vehicles. State and local governments acquire ablukast sodium primarily through multistate cooperative purchasing alliances and statewide pharmaceutical contracts that consolidate demand across participating agencies and authorized wholesalers, enabling negotiated pricing and streamlined distribution. The scope reflects the procurement of finished pharmaceutical products meeting FDA requirements, cGMP certification, and DSCSA compliance, with vendors required to supply through established distribution channels and maintain comprehensive product data including NDC codes, SKUs, UPCs, strength, dosage form, and packaging configurations. Issuing bodies under this code include state departments of administration, multistate cooperative purchasing consortia, and subordinate state and local healthcare agencies that participate in centralized pharmaceutical contracting frameworks.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (due March 26, 2026) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products distributed across participating state and local government facilities, including Oregon. The MMCAP RFP requires vendors to supply through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—and emphasizes price competitiveness (weighted at 75 percent of evaluation), compliance with EDI capability and administrative fee data formats, and cGMP and DSCSA certification. Awarded vendors must maintain contractual relationships with at least two of the three authorized wholesalers, carry commercial general liability insurance of $5,000,000 per occurrence, and agree to a 3 percent administrative fee on all contract purchases. The contract term is two years for new responders with optional extensions at MMCAP's sole discretion, with performance effective July 1, 2026.